Where peptide leaders meet to build successful partnerships & accelerate products across all development phases
Increase half-life & minimise manufacturing costs through new data, case studies & technologies for peptide therapeutics
Lead optimisation strategies to improve drug-like properties for next generation peptide therapeutics
- Peptide therapeutics beyond metabolic diseases
Where are the future opportunities?
- Overcome the challenges of translating early leads into the clinic - Zeal& Pharma & Amgen provide successful lead optimisation & engineering insights
- New frontiers in peptide design鈥� What are the latest developments in peptide vaccines, conjugates, macrocyclic & antimicrobial peptides?
- Increasing the half-life, targeting & stability of peptide products 鈥� What are the cutting edge methodologies to move to longer exposure times?
New techniques for improved administration of peptide products
- Preclinical & clinical developments of complex peptides 鈥� What are the most exciting products advancing through the clinic?
- Benchmark your clinical programmes with case studies insights from Bicycle Therapeutics & Polyphor
- Non-invasive delivery methods - What are the latest advances in orally bioavailable, transdermal & controlled release peptides?
- Formulation strategies 鈥� Which are the winning techniques & technologies for sustained release?
Latest developments in large scale peptide manufacturing to reduce cost of goods
- Optimising process development, CMC & large scale manufacturing - How are industry overcoming the challenges of peptide scale up & production?
- Solid phase synthesis 鈥� Which new coupling methods & linkers can improve manufacturing efficiency?
220+ Decision Makers
110+ Companies from the Oligonucleotide & Peptide Industry
65:35 Buyer: Seller Ratio
Increase half-life & minimise manufacturing costs through new data, case studies & technologies for peptide therapeutics
Lead optimisation strategies to improve drug-like properties for next generation peptide therapeutics
- Peptide therapeutics beyond metabolic diseases
Where are the future opportunities?
- Overcome the challenges of translating early leads into the clinic - Zeal& Pharma & Amgen provide successful lead optimisation & engineering insights
- New frontiers in peptide design鈥� What are the latest developments in peptide vaccines, conjugates, macrocyclic & antimicrobial peptides?
- Increasing the half-life, targeting & stability of peptide products 鈥� What are the cutting edge methodologies to move to longer exposure times?
New techniques for improved administration of peptide products
- Preclinical & clinical developments of complex peptides 鈥� What are the most exciting products advancing through the clinic?
- Benchmark your clinical programmes with case studies insights from Bicycle Therapeutics & Polyphor
- Non-invasive delivery methods - What are the latest advances in orally bioavailable, transdermal & controlled release peptides?
- Formulation strategies 鈥� Which are the winning techniques & technologies for sustained release?
Latest developments in large scale peptide manufacturing to reduce cost of goods
- Optimising process development, CMC & large scale manufacturing - How are industry overcoming the challenges of peptide scale up & production?
- Solid phase synthesis 鈥� Which new coupling methods & linkers can improve manufacturing efficiency?
220+ Decision Makers
110+ Companies from the Oligonucleotide & Peptide Industry
65:35 Buyer: Seller Ratio
